Invasive Zygomycosis: Epidemiology and Clinical Features (Review)

INFECTIONS IN ONCOHEMATOLOGY ,

NS Bagirova

N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Nataliya Sergeevna Bagirova, DSci, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel.: +7(499)324-18-60; e-mail: nbagirova@mail.ru

For citation: Bagirova NS. Invasive Zygomycosis: Epidemiology and Clinical Features (Review). Clinical oncohematology. 2016;9(1):84–9 (In Russ).

DOI: 10.21320/2500-2139-2016-9-1-84-89

ABSTRACT

The invasive zygomycosis is the third most common mycosis following invasive candidiasis and aspergillosis. Patients with hematological malignancies and patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are two main risk groups for the disease. In addition, zygomycosis is important for patients with diabetes. The review presents detailed description of epidemiology, risk factors, clinical types of zygomycosis, and features of therapy.

Keywords: zygomycosis, invasive zygomycosis, Zygomycetes.

Received: October 9, 2015

Accepted: November 1, 2015

Read in PDF (RUS) pdficon

REFERENCES

  1. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and Clinical Manifestations of Mucormycosis. Clin Infect Dis. 2012;54(S1):S23–34. doi: 10.1093/cid/cir866.
  2. Skiada A, Pagano L, Groll A, et al. European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67. doi: 10.1111/j.1469-0691.2010.03456.x.
  3. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20(Suppl. 6):74–81. doi: 10.1111/1469-0691.12466.
  4. Zilberberg MD, Shorr AF, Huang H, et al. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis. 2014;14:310. doi: 10.1186/1471-2334-14-310.
  5. Blandine R, Lanternier F, Zahar J-R, et al. Healthcare-associated mucormycosis. Clin Infect Dis. 2012;54(Suppl. 1):S44–54. doi: 10.1093/cid/cir867.
  6. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301. doi: 10.1128/cmr.13.2.236-301.2000.
  7. Shenoi S, Emery HM. Successful treatment of invasive gastric mucormycosis in a child with systemic lupus erythematosus. Lupus. 2010;19:646–9. doi: 10.1177/0961203309349117.
  8. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8. doi: 10.1182/blood-2010-02-268151.
  9. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–27. doi: 10.1111/j.1365-2141.2011.08838.x.
  10. Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723–7. doi: 10.1097/inf.0b013e318062115c.
  11. Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary mucormycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6. doi: 10.1086/430710.
  12. Wahba H, Truong MT, Lei X, et al. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46:1733–7. doi: 10.1086/587991.
  13. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of mucormycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53. doi: 10.1086/432579.
  14. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52:1573–6. doi: 10.1128/aac.01488-07.
  15. Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2007;51:1253–8. doi: 10.1128/aac.01449-06.
  16. Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54:1298–304. doi: 10.1128/aac.01222-09.
  17. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9. doi: 10.1086/590004.
  18. Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(Suppl. 1):S55–60. doi: 10.1093/cid/cir868.
  19. Lewis RE, Lortholary O, Spellberg B, et al. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis. 2012;54(Suppl. 1):S67–72. doi: 10.1093/cid/cir884.